PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

A more nuanced approach to the evidence standard for prior use (T 1311/21)

  • Sector: Chemistry
  • 7th February 2025
The EPO provides crucial guidance on the standard of proof in alleged prior use cases, advocating for a nuanced approach.
 

This post is based on a previous article on IPKat.

The decision of the EPO Board of Appeal in T 1311/21 provides important guidance on evaluating standards of proof in cases of alleged prior use. The Board of Appeal suggests that there should be a nuanced approach to assessing this evidence, that moves beyond the traditional binary choice between the “balance of probabilities” and “beyond reasonable doubt”. 

Background: Evidence standard for prior use

Traditionally, EPO Boards of Appeal have applied different standards of proof depending on whether evidence of alleged prior use was within the power of one party or equally available to both parties. The case at issue concerned European patent EP2950075, owned by Horiba Ltd, relating to an on-road running exhaust gas test apparatus. The patent claimed an apparatus for vehicle exhaust gas testing comprising an information processing unit connected to a display that could acquire and process running data during road tests. The Opponent, Avl List GmbH, challenged the patent’s validity based on several grounds, including prior public use as evidenced by a user manual describing the invention. 

At Opposition, the patent was maintained in amended form, with the Opposition Division (OD) finding that disclosure of the invention prior to the priority date had not been proven. Both parties appealed the OD decision. The question for the Board of Appeal was whether the user manual had been made available to the public before the priority date without an obligation of confidentiality, and how to assess the standard of proof required given that the evidence was neither fully within the opponent’s control nor equally accessible to both parties.

A more nuanced standard to the assessment of evidence for prior use? 

In T 1311/21, the Board of Appeal addressed the longstanding dichotomy between “balance of probabilities” and “beyond reasonable doubt” standards, and questions whether such a dichotomy in fact made sense. The Board of Appeal noted that EPO case law has applied different standards depending on whether evidence lies within the power of one party (requiring proof “beyond reasonable doubt”) or is equally available to both parties (where “balance of probabilities” suffices). However, in this case, the evidence of prior use fell into neither category cleanly. Whilst the manual originated from the Opponent, it had been delivered to a third party (Daimler AG) and the circumstances of its use were not exclusively within either party’s knowledge.

The Board of Appeal observed that a “binary approach to proof standards can turn out to be overly formalistic and simplistic” (headnote 2). Instead, the Board of Appeal emphasised that “what matters is the deciding body’s conviction on the occurrence of an alleged fact, taking into account the particular circumstances of the case and the relevant evidence before it.” (headnote 2, and r. 3.2.1). In support of moving away from an approach based on a rigid dichotomy, the Board of Appeal cited previous decisions T 1138/20 and T 1634/17. T 1138/20, for example, found that making a distinction between the above-mentioned standards is neither necessary nor mandated by case law. Similarly, in T 1634/17, it was found that there was no need to take a stand on the question which standard of proof to apply.

In the present case, the Board of Appeal was of the view that applying a more flexible approach to the assessment of evidence would align with the complex reality of many prior use cases, where evidence may be partially available to both parties, or may lie primarily with third parties. Rather than trying to force such situations into one of two categories, the Board of Appeal advocated for a holistic assessment of the evidence in its context. 

Importantly, however, the Board of Appeal also emphasised that the more flexible approach to assessing the evidence for prior use it proposed would not mean a lowering of the bar for proving prior use. On the contrary, the Board of Appeal argued, it would mean a greater focus on whether the totality of evidence, considered in its proper context, was convincing of an alleged prior use. Such an approach might include consideration of factors such as the nature of the alleged use, the commercial context, the reliability of the evidence, and any circumstances that might affect its availability to the parties.

Reliance on general terms of confidentiality 

Having decided on what approach it should take, the Board of Appeal reviewed the chain of evidence regarding the public availability of the a user manual for the AVL MOVE System Control software. The OD had found the user manual not to be prior art, and so had not fully considered the novelty and inventive step of the claim invention in view of the manual. Key evidence cited by the Opponent that the manual should be considered prior art included delivery notes showing the shipment of the user manual to another company, Daimler AG. The Board of Appeal was convinced by this evidence that the relevant version of the manual was delivered to Daimler AG before the patent’s priority date. 

The question then became whether conditions of confidentiality could be said to have applied to the manual. The Board rejected arguments from the patentee that the confidentiality of the manual was implied. Particularly, the Board of Appeal noted that user manuals for commercially available products are typically not subject to confidentiality obligations. 

The patentee also referenced the mention of AVL’s General Terms and Conditions in the delivery note and also noted standard industry practice. However, the Board of Appeal was not convinced by these arguments. First, the Board emphasised the commercial reality that the AVL MOVE system described in user manual was not a product produced for a single customer, but for many, with the manual intended for delivery to all purchasers. The Board noted that imposing confidentiality obligations on such widely distributed user manuals would be impractical and nearly impossible to enforce. The Board emphasised that user manuals, by their nature, merely describe how to use an already purchased product and thus wouldn’t typically be subject to confidentiality restrictions. Additionally, the cited purchase documentation revealed that Daimler AG’s own purchasing conditions were applicable to the case, potentially neutralising any effect of AVL’s standard terms. 

The Board of Appeal concluded that the user manual was prior art and remitted the case back to the Opposition Division for an assessment of novelty and inventive step.

Final Thoughts

The issue of prior use is, of course, a hot topic at the moment as we await the outcome of the referral to the EBA in G1/23. The issue also came up in the recent decision concerning the morality of inventions derived from indigenous people by immoral means. As the Board of Appeal notes in the present case, both demonstrating or defending against an allegation of prior use can be challenging, as the form of evidence is often less than perfect. 

The Board of Appeal’s approach in this case suggests that future cases involving prior use should focus less on arguing about which standard of proof applies, and more on presenting comprehensive evidence that allows the deciding body to form a clear conviction about what occurred.

Further Reading

  • New EBA referral: When is prior use of a product excluded from the prior art for lack of enablement? 
  • The morality (and patentability) of inventions derived by immoral means (T 2510/18)

Related insights...

Divergence between the UPC and EPO on claim interpretation and description definitions (Agfa v Gucci, UPC_CFI_278/2023)

  • 12th August 2025
A new ruling in Agfa v Gucci reveals a split between the UPC and the EPO on claim interpretation, with the UPC using a patent’s own ‘lexicon’ to narrow a claim, a decision with major implications for patent holders in Europe.

An “immunogenic composition” is not a vaccine (T 0070/23)

  • 8th August 2025
While G1/24 mandates consulting the description, T 0070/23 is a crucial reminder of its limits. The case shows how the Board of Appeal refused to let a description definition override the clear technical meaning of a product claim.

Referral on description amendments finally confirmed (G1/25 – “Hydroponics”)

  • 29th July 2025
At last, the wait is over. After years of conflicting case law and mounting frustration for practitioners, the Enlarged Board of Appeal is set to rule on the controversial issue of description amendments in G1/25. But will the decision actually bring clarity?

G 1/24 in the spotlight: Description definitions do not override clear claim language (T 1999/23)

  • 24th July 2025
The latest decision from the EPO to apply the landmark decision in G1/24 on claim interpretation finds that description definitions should not override clear claim lanaguge.

The problem with product-by-process patents (T 1065/23)

  • 18th July 2025
Inventions may be defined in a patent as product, a process, or a product defined by the process that it is made. The choice of patent claim format you choose to define the invention can be highly influential to validity and enforcement later on.

First interpretation of G 1/24 (the description must always be consulted) (T 1561/23)

  • 14th July 2025
Did G1/24 really change everything about claim interpretation, or does it simply formalize what Boards of Appeal were already doing case-by-case?”

Pitfalls of cell therapy manufacturing IP – A case study (T 0868/23)

  • 8th July 2025
In cell therapy the industry mantra is that the product is the process. However, this case illustrates that the best patent protection for a cell therapy is derived from the product. 

Non-reproducible commercial products are prior art (G1/23)

  • 7th July 2025
Is your product prior art if you disclose it before you file your patent, but without disclosing how it is made or what it is made from? The EBA answers “yes”.

The morality (and patentability) of inventions derived by immoral means (T 2510/18)

  • 25th June 2025
Should patents be granted for inventions born from unethical practices, even if they offer significant societal benefits?

How to read a biotech patent

  • 23rd June 2025
Learn how to quickly search for and extract key information from biotech patent documents.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2025 All Rights Reserved

Keep in touch

Subscribe

Contact Us